Abstract
The delineation of the molecular basis of cancer in general, allows for the possibility of specific intervention at the molecular level for therapeutic purposes. To this end, three main approaches have been developed: mutation compensation, molecular chemotherapy, and genetic immunopotentiation. The strategy of mutation compensation aims to correct the specific genetic defects in cancer cells. Such correction is accomplished by either ablation of oncogenic products, replacement of cellular tumor suppressor genes, or interference with dysregulated signal transduction pathways. A second strategy is molecular chemotherapy, which aims to increase the specificity of drug delivery or to increase tolerance to standard chemotherapeutic regimens. A third strategy, genetic immunotherapy, aims to augment the specificity and/or the magnitude of the normal immune response to tumors. For each of these conceptual approaches, human clinical protocols have entered Phase I clinical trials to assess dose escalation, safety, and toxicity issues.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Krol, A.V. and Stuitje, A. R. (1988) Modulation of eukaryotic gene expression by complement RNA or DNA sequences. Biotechniques 6, 958–976.
Helene, C. and Toulme, J-J. (1990) Specific regulation of gene expression by antisense, sense, and antigene nucleic acids. Biochem. Biophys. 1049, 99–125.
Gibson, I. (1996) Antisense approaches to the gene therapy of cancer. Cancer Metastasis Rev. 15, 287–299.
Milligan, J. F., Jones, R. J., Froehler, B. C., and Matteucci, M. D. (1994) Development of antisense therapeutics. Implications for cancer gene therapy. Ann. NY Acad. Sci. 716, 228–241.
Stein, C. A. and Cheng, Y-C. (1993) Antisense oligonucleotides as therapeutic agents-is the bullet really magic? Science 261, 1004–1012.
Stein, C. A. (1995) Does antisense exist? Nat. Med. 1, 1119–1121.
Theuer, C. P. and Pastan, I. (1993) Immunotoxins and recombinant toxins in the treatment of solid carcinomas. Amer. J. Surg., 166, 284–288.
Brinkmann, U., Pai, L. H., and FitzGerald, D. J. (1991) B3-(Fv)-PE38KDEL, a single chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA 88, 8616–8620.
Hoogenboom, H. R., Marks, J. D., Griffiths, A. D., and Winter, G. (1992) Building antibodies from their genes. Immunol. Rev. 130, 41–68.
Jost, C. R., Kurucz, I., Jacobus, C. M., Titus, J. A., George, A. J., and Segal, D. M. (1994) Mammalian expression and secretion of functional single-chain Fv molecules. J. Biol. Chem. 269, 26,267–26,273.
Richardson, J. H. and Marasco, W. A. (1995) Intracellular antibodies: development and therapeutic potential. Trends Biotech. 13, 306–310.
Chen, S. Y., Bagley, J., and Marasco, W. A. (1994) Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum. Gene Ther. 5, 595–601.
Colcher, D., Bird, R., and Roselli, M. (1990) In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Can. Inst. 82, 1191–1197.
Wawrzynczak, E. J. (1992) Rational design of immunotoxins: current progress and future prospects. Anti-Cancer Drug Design 7, 427–441.
Mykebust, A. T., Godal, A., and Fodstad, O. (1994) Targeted therapy with immunotoxins in a nude rat model for leptomenineal growth of human small cell cancer. Cancer Res. 54, 2146–2150.
Marasco, W. A., Haseltine, W. A., and Chen, S-Y. (1993) Design, intracellular expression, and activity of human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. USA 90, 7889–7893.
Friedman, P. N., Chance, D. F., and Trail, P. A. (1993) Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. J. Immunol. 150, 3054–3061.
Werge, T. M., Biocca, S., and Cattaneo, A. (1990) Cloning andintracellular expression of a monoclonal antibody to the p21ras protein. FEBS Lett. 274, 193–198.
Deshane, J., Loechel, F., Conry, R. M., Siegal, G. P., King, C. R., and Curiel, D. T. (1994) Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gen. Ther. 1, 332–337.
Deshane, J., Siegal, G. P., Alvarez, R. D., Wang, M. H., Feng, M., Cabrera, G., et al. (1995) Targeted tumor killing via an intracellular antibody against erbB-2. J. Clinic. Investigat. 96, 2980–2989.
Deshane, J., Grim, J., Loechel, S., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. (1996) Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther. 3, 89–98.
Grim, J., Deshane, J., Feng, M., Lieber, A., Kay, M., and Curiel, D. T. (1996) erbB-2 knockout employing an intracellular single-chain antibody (sFv) accomplishes specific toxicity in erbB-2-expressing lung cancer cells. Amer. J. Respir. CellMolec. Biol. 15, 348–354.
Barnes, D. M., Deshane, J., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. (1996) Novel gene therapy strategy to accomplish growth factor modualtion induces enhanced tumor cell chemosensitivity. Clinic. Cancer Res. 2, 1089–1095.
Wright, M., Grim, J., Kim, M., Strong, T. V., Siegal, G. P., and Curiel, D. T. (1997) An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther. 4, 317–322.
Kim, M., Wright, M., Deshane, J., Accavitti, M. A., Tilden, A., Saleh, et al. (1997) A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow. Human Gene Ther. 8, 157–170.
Curiel, D. T. Targeted tumor cytotoxicity mediated by intracellular single-chain antioncogene antibodies in Gene Therapy in Advances in pharmacology (Thomas August, J., ed.), Academic, New York, Vol. 40, pp. 51–84.
McCafferty, J., Griffiths, A. D., Winter, G., and Chriswell, D. J. (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554.
Rodenburg, C., Mernaugh, R., Bilbao, G., and Khazaeli M. B. (1998) Production of a single cahin anti-CEA antibody from the hybridoma cell line T84.66 using a modified colony-lift selection procedure to detect antigen-positive scFv bacterial clones. Hybridoma 17, 1–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Bilbao, G., Gomez-Navarro, J., Kazano, K., Luis Contreras, J., Curiel, D.T. (2000). 9 Intracellular Single-Chain Antibodies for Gene Therapy. In: Walther, W., Stein, U. (eds) Gene Therapy of Cancer. Methods in Molecular Medicine™, vol 35. Humana Press. https://doi.org/10.1385/1-59259-086-1:121
Download citation
DOI: https://doi.org/10.1385/1-59259-086-1:121
Publisher Name: Humana Press
Print ISBN: 978-0-89603-714-4
Online ISBN: 978-1-59259-086-5
eBook Packages: Springer Protocols